Merck beats by $0.10, beats on revs; guides FY15 EPS in-line, revs in-line
Reports Q1 (Mar) earnings of $0.85 per share, excluding non-recurring items, $0.10 better than the Capital IQ Consensus Estimate of $0.75; revenues fell 8.2% year/year to $9.43 bln vs the $9.06 bln consensus.
- Co issues in-line guidance for FY15, sees EPS of $3.35-3.48, excluding non-recurring items, vs. $3.37 Capital IQ Consensus Estimate; sees FY15 revs of $38.3-39.8 bln vs. $39.23 bln Capital IQ Consensus Estimate.